liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Economic evaluation of screening for prostate cancer: a randomized populaionbased programme during a 10 year period in Sweden
Linköping University, Department of Department of Health and Society, Center for Medical Technology Assessment. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Department of Health and Society, Center for Medical Technology Assessment. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Department of Health and Society. Linköping University, Faculty of Health Sciences.
Department of Surgery and Urology, County Hospital, Norrköping, Sweden.
1998 (English)In: Health Policy, ISSN 0168-8510, Vol. 45, no 2, 133-147 p.Article in journal (Refereed) Published
Abstract [en]

Prostate cancer is a growing health problem representing considerable costs. Screening and early curative treatment may reduce morbidity and possibly prevent future escalating costs. However, population screening programmes are generally not well accepted at present due to uncerainty about whether screening for prostate cancer can result in reduced mortality. Evidence from large, randomized, controlled trials is still lacking. The objective of this study was to calculate clinical and economic consequences of general prostate cancer screening based on a limited screening trial in a Swedish community and a decision-tree model. A random selection of 1492 men (50–69 years) were invited to repeated screening in 1987. They have been examined every third year (four rounds). The other 7679 men in the population act as controls. The results show that the total incremental health care costs for prostate cacer will increase by 179 million SEK per year with screening compared to no-screening. The number of detected cases of localized cancer will increase by about 1000, which represents an additional cost of about 158 000 SEK per case. In conclusion, general screening for prostate cancer can be performed with a reasonable cost per detected localized cancer. Information on the long-term effect on life quality and cancer mortality is unknown.

Place, publisher, year, edition, pages
1998. Vol. 45, no 2, 133-147 p.
National Category
Social Sciences Interdisciplinary
Identifiers
URN: urn:nbn:se:liu:diva-32386DOI: 10.1016/S0168-8510(98)00037-2Local ID: 18286OAI: oai:DiVA.org:liu-32386DiVA: diva2:253208
Available from: 2009-10-09 Created: 2009-10-09 Last updated: 2012-09-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Carlsson, PerLöfman, OweVarenhorst, Eberhard

Search in DiVA

By author/editor
Carlsson, PerLöfman, OweVarenhorst, Eberhard
By organisation
Center for Medical Technology AssessmentFaculty of Health SciencesDepartment of Department of Health and Society
In the same journal
Health Policy
Social Sciences Interdisciplinary

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 238 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf